Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System

被引：9

作者：

Frei, Christopher R. ^{[1
,2
,3
]}

Le, Hannah ^{[4
]}

McHugh, Daniel ^{[4
]}

Ryan, Kellie ^{[4
]}

Jones, Xavier ^{[1
,2
,3
]}

Galley, Samantha ^{[1
]}

Franklin, Kathleen ^{[1
]}

Baus, Courtney J. ^{[2
,3
]}

Tavera, Juan ^{[1
]}

Janania-Martinez, Michelle ^{[1
]}

Gregorio, David ^{[1
]}

Ananth, Snegha ^{[1
]}

Uribe, Ricardo ^{[1
]}

Surapaneni, Prathibha ^{[1
]}

Espinoza-Gutarra, Manuel ^{[1
]}

Song, Michael M. ^{[1
]}

Teng, Chengwen ^{[5
]}

Obodozie-Ofoegbu, Obiageri O. ^{[2
,3
]}

Nooruddin, Zohra ^{[1
,3
]}

机构：

[1] South Texas Vet Hlth Care Syst, San Antonio, TX USA

[2] Univ Texas Austin, Coll Pharm, San Antonio, TX USA

[3] Univ Texas Hlth San Antonio, Long Sch Med, San Antonio, TX 78229 USA

[4] AstraZeneca US Med Affairs, Gaithersburg, MD USA

[5] Univ South Carolina, Coll Pharm, Dept Clin Pharm & Outcomes Sci, Columbia, SC 29208 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 07期

关键词：

Chronic lymphocytic leukemia; adverse events; novel agents; discontinuation; dose reduction; chart review; IBRUTINIB; IDELALISIB; RITUXIMAB; DISCONTINUATION;

D O I：

10.1080/10428194.2021.1876863

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with a novel oral agent. For 1L ibrutinib, 33% (n = 107) discontinued therapy during the study, of which 64% discontinued due to adverse events (AEs). For relapsed/refractory (R/R) ibrutinib, 35% (n = 262) discontinued therapy, of which 63% discontinued due to AEs. For R/R venetoclax, 31% (n = 27) discontinued therapy, of which 41% were due to AEs. For idelalisib, 84% (n = 41) discontinued therapy, of which 54% were due to AEs. This real-world study suggests that AEs play an important role in dose reductions and discontinuations; however, physician inexperience in using these drugs when they were first introduced could be part of what is leading to these negative outcomes.

引用

页码：1664 / 1673

页数：10

共 30 条

[1] [Anonymous], 2018, ZYD IDEL TABL
[2] [Anonymous], 2020, VENCL VEN TABL
[3] [Anonymous], 2019, CALQUENCE ACALABRUTI
[4] Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Barr, Paul M.
Robak, Tadeusz
Owen, Carolyn
Tedeschi, Alessandra
Bairey, Osnat
Bartlett, Nancy L.
Burger, Jan A.
Hillmen, Peter
Coutre, Steven
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Simpson, David
Offner, Fritz
Moreno, Carol
Zhou, Cathy
Styles, Lori
James, Danelle
Kipps, Thomas J.
Ghia, Paolo
[J]. HAEMATOLOGICA, 2018, 103 (09) : 1502 - 1510
[5] Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Brown, Jennifer R.
Byrd, John C.
Coutre, Steven E.
Benson, Don M.
Flinn, Ian W.
Wagner-Johnston, Nina D.
Spurgeon, Stephen E.
Kahl, Brad S.
Bello, Celeste
Webb, Heather K.
Johnson, Dave M.
Peterman, Sissy
Li, Daniel
Jahn, Thomas M.
Lannutti, Brian J.
Ulrich, Roger G.
Yu, Albert S.
Miller, Langdon L.
Furman, Richard R.
[J]. BLOOD, 2014, 123 (22) : 3390 - 3397
[6] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A.
Tedeschi, A.
Barr, P. M.
Robak, T.
Owen, C.
Ghia, P.
Bairey, O.
Hillmen, P.
Bartlett, N. L.
Li, J.
Simpson, D.
Grosicki, S.
Devereux, S.
McCarthy, H.
Coutre, S.
Quach, H.
Gaidano, G.
Maslyak, Z.
Stevens, D. A.
Janssens, A.
Offner, F.
Mayer, J.
O'Dwyer, M.
Hellmann, A.
Schuh, A.
Siddiqi, T.
Polliack, A.
Tam, C. S.
Suri, D.
Cheng, M.
Clow, F.
Styles, L.
James, D. F.
Kipps, T. J.
Keating, Michael
Jen, Jie
Jindra, Pavel
Simkovic, Martin
Braester, Andrei
Ruchlemer, Rosa
Foa, Roberto
Semenzato, Gianpietro
Hawkins, Timothy
Atanasio, Carolina Moreno
Demirkan, Fatih
Kaynar, Leylagul
Pylypenko, Halyna
Fox, Christopher
Thirman, Michael
Campbell, Philip
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) : 2425 - 2437
[7] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Burger, Jan A.
Barr, Paul M.
Robak, Tadeusz
Owen, Carolyn
Ghia, Paolo
Tedeschi, Alessandra
Bairey, Osnat
Hillmen, Peter
Coutre, Steven E.
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Simpson, David
Offner, Fritz
Moreno, Carol
Dai, Sandra
Lal, Indu
Dean, James P.
Kipps, Thomas J.
[J]. LEUKEMIA, 2020, 34 (03) : 787 - 798
[8] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C.
Brown, J. R.
O'Brien, S.
Barrientos, J. C.
Kay, N. E.
Reddy, N. M.
Coutre, S.
Tam, C. S.
Mulligan, S. P.
Jaeger, U.
Devereux, S.
Barr, P. M.
Furman, R. R.
Kipps, T. J.
Cymbalista, F.
Pocock, C.
Thornton, P.
Caligaris-Cappio, F.
Robak, T.
Delgado, J.
Schuster, S. J.
Montillo, M.
Schuh, A.
de Vos, S.
Gill, D.
Bloor, A.
Dearden, C.
Moreno, C.
Jones, J. J.
Chu, A. D.
Fardis, M.
McGreivy, J.
Clow, F.
James, D. F.
Hillmen, P.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) : 213 - 223
[9] Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Byrd, John C.
Hillmen, Peter
O'Brien, Susan
Barrientos, Jacqueline C.
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine S.
Mulligan, Stephen P.
Jaeger, Ulrich
Barr, Paul M.
Furman, Richard R.
Kipps, Thomas J.
Thornton, Patrick
Moreno, Carol
Montillo, Marco
Pagel, John M.
Burger, Jan A.
Woyach, Jennifer A.
Dai, Sandra
Vezan, Remus
James, Danelle F.
Brown, Jennifer R.
[J]. BLOOD, 2019, 133 (19) : 2031 - 2042
[10] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, John C.
Furman, Richard R.
Coutre, Steven E.
Flinn, Ian W.
Burger, Jan A.
Blum, Kristie A.
Grant, Barbara
Sharman, Jeff P.
Coleman, Morton
Wierda, William G.
Jones, Jeffrey A.
Zhao, Weiqiang
Heerema, Nyla A.
Johnson, Amy J.
Sukbuntherng, Juthamas
Chang, Betty Y.
Clow, Fong
Hedrick, Eric
Buggy, Joseph J.
James, Danelle F.
O'Brien, Susan
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) : 32 - 42

← 1 2 3 →